PATENT 1151-4158US1 US.S.N. 09/701,588

Jan-18-2002 04:36pm

A peptide immunogen according to Claim 13 selected form the group consisting 14. of SEQ ID NOs:148 - 150, and 151.

A marked-up version of the amended claims is in the Appendix attached hereto.

REMARKS

Claims 1, 2, 9, 11, 13 and 14 have been amended to recite the Markush group in proper language. Support for the amendment is found in originally filed Claims 1, 2 9, 11, 13 and 14. No new matter is presented. Entry of the amendment is requested.

RESPONSE

Claims 1, 2, 9, 11, 13 and 14 were rejected as indefinite by the Examiner for using Markush group language that is incorrect in claim 1, line 2, claim 2, line 20, claims 9, 11, 13 and 14, line 2. Claims 1, 2, 9, 11, 13 and 14 have been amended to correctly recite the Markush groups. Reconsideration of the rejection is requested.

As amended the claims employ correct Markush language and the rejection on this ground has been overcome and is now moot. It is clear that the amendment does not narrow the scope of the invention originally claimed.

The Examiner indicated that the claims distinguish over prior all and are allowable if amended.

Claims 3-8, 10, 12 and 15-33 have been allowed. It is believed that as amended claims 1, 2, 9, 11, 13 and 14 are allowable and an early allowance is requested.

Respectfully submitted

Date: <u>January 18, 2002</u>

Registration No. 29,323

Morgan & Finnegan, L.L.P. 345 Park Avenue New York, New York 10154 Tel. No. (212) 758-4800 Fax. No. (212) 751-6849

Direct Line: (212) 415-8745

- 3 -

676393 -1